Luis Caraballo, Richard Lockey, Leonardo Puerta, Josefina Zakzuk, Nathalie Acevedo, Enrique Fernández-Caldas
{"title":"Blomia tropicalis: A 50 Year History.","authors":"Luis Caraballo, Richard Lockey, Leonardo Puerta, Josefina Zakzuk, Nathalie Acevedo, Enrique Fernández-Caldas","doi":"10.1016/j.jaip.2024.11.007","DOIUrl":null,"url":null,"abstract":"<p><p>The genus Blomia tropicalis was described fifty years ago. Since then, great progress has been made on the clinical impact of this house dust mite (HDM). B. tropicalis is widely distributed in tropical and subtropical zones, where it induces IgE sensitization and clinical symptoms. The discovery of this mite not only provided additional support for the causal relationship between HDM sensitization and allergic respiratory symptoms but also changed the scope of the diagnosis and management of these diseases. There are now 26 officially accepted B. tropicalis allergens, several of them with cross-reactivity with mites such as Dermatophagoides spp. and some storage mites, which adds complexity to the diagnosis of sensitization and the choice of extracts for allergen specific immunotherapy. Fortunately, the discovery and characterization of molecules useful for component resolved diagnostic testing provide the tools for this challenge. Immunotherapy with B. tropicalis extract is successfully used in several countries of Latin America, Africa and Asia; however, the availability of standardized extracts in subtropical regions is still limited. During the 50 years of research on B. tropicalis, several groups, have made contributions about allergen characterization, their mechanisms of action and clinical impact; the immunogenetics of sensitization; the possible effects of climate change; and the design and testing of new vaccines.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2024.11.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
The genus Blomia tropicalis was described fifty years ago. Since then, great progress has been made on the clinical impact of this house dust mite (HDM). B. tropicalis is widely distributed in tropical and subtropical zones, where it induces IgE sensitization and clinical symptoms. The discovery of this mite not only provided additional support for the causal relationship between HDM sensitization and allergic respiratory symptoms but also changed the scope of the diagnosis and management of these diseases. There are now 26 officially accepted B. tropicalis allergens, several of them with cross-reactivity with mites such as Dermatophagoides spp. and some storage mites, which adds complexity to the diagnosis of sensitization and the choice of extracts for allergen specific immunotherapy. Fortunately, the discovery and characterization of molecules useful for component resolved diagnostic testing provide the tools for this challenge. Immunotherapy with B. tropicalis extract is successfully used in several countries of Latin America, Africa and Asia; however, the availability of standardized extracts in subtropical regions is still limited. During the 50 years of research on B. tropicalis, several groups, have made contributions about allergen characterization, their mechanisms of action and clinical impact; the immunogenetics of sensitization; the possible effects of climate change; and the design and testing of new vaccines.
期刊介绍：
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
